The Cost of Drug Approval Delays

This chapter examines the serious implications of regulatory delays in drug approval, particularly through the lens of the Dallas Buyers Club case. It discusses the need for reform within institutions like the FDA and explores the complicated dynamics between government, pharmaceutical companies, and alternative healthcare solutions. Through personal narratives and critiques of bureaucratic practices, the conversation emphasizes the urgent necessity for change in the healthcare regulatory landscape.